In early January, Ugur Sahin, a Turkish-born immunology professor, told the board of the German biotech group he co-founded to devote the small company’s resources to tackling a new virus that had emerged in China.
Eleven months later, BioNTech’s Covid-19 vaccine — developed with the help of US partner Pfizer and China’s Fosun — is on course to become the first approved vaccination in the US and EU for the disease that has killed 1.25m people and battered the world economy.
The inoculation, based on mRNA technology that has never been used before, was found to be 90 per cent effective in phase 3 trials involving more than 43,000 participants, the companies said on Monday, far exceeding the threshold required by regulators.
您已阅读13%（730字），剩余87%（4688字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。